A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.
Gilead Sciences' Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute lymphoblastic leukaemia (ALL) in Europe, free of direct competition from arch-
The EU has blocked the merger of Illumina and Grail, saying the deal would stifle innovation in blood-based diagnostics for cancer diagnostics, just days after a bid by the US authorities t
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in
A judge in the US has ruled in favour of Illumina in a dispute with the Federal Trade Commission (FTC) over its multibillion-dollar takeover of cancer diagnosis specialist Grail, which had
Sanofi now has approval on both sides of the Atlantic for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after getting a green light f
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer.